| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/25/2002 | CA2425763A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 04/25/2002 | CA2425742A1 Methods of selecting compounds for modulation of bladder function |
| 04/25/2002 | CA2425727A1 Methods and compositions for promoting the maturation of monocytes |
| 04/25/2002 | CA2425699A1 Medicinal composition and in particular its use in fluid therapy |
| 04/25/2002 | CA2425522A1 Ribavirin-pegylated interferon alfa hcv combination therapy |
| 04/25/2002 | CA2425310A1 Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol |
| 04/25/2002 | CA2425174A1 Human gene critical to fertility |
| 04/25/2002 | CA2424345A1 Liposomal formulation of mitoxantrone |
| 04/25/2002 | CA2423792A1 Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| 04/25/2002 | CA2423013A1 Use of inhibitors of progesteron receptor for treating cancer |
| 04/25/2002 | CA2419388A1 Substituted dipeptides as growth hormone secretagogues |
| 04/24/2002 | EP1199372A2 Polymorphisms in the human P2X7 gene |
| 04/24/2002 | EP1199304A1 Bicyclic compounds and pharmaceutical composition containing tricyclic compound for treating or preventing sleep disorders |
| 04/24/2002 | EP1199077A1 Stable compositions of oxapenem-3-carboxylic acids by Co-lyophilisation with pharmaceutical carriers |
| 04/24/2002 | EP1199070A2 Use of PDE V inhibitors for improved fecundity in mammals |
| 04/24/2002 | EP1199069A2 Use of an estrogen agonist/antagonist for assessing, improving, or maintaining urogenital health |
| 04/24/2002 | EP1199068A2 NMDA NR2B antagonists for treating depression and neurodegenerative disorders |
| 04/24/2002 | EP1199067A2 Prophylactic use of N-Methyl-D-Aspartate (NMDA) antagonists |
| 04/24/2002 | EP1198995A1 Anti-stress composition for incorporation in nutritional carriers |
| 04/24/2002 | EP1198589A1 Tenascin-c nucleic acid ligands |
| 04/24/2002 | EP1198568A1 Compositions and methods for the treatment of immune related diseases |
| 04/24/2002 | EP1198563A2 Novel fibroblast growth factor and nucleic acids encoding same |
| 04/24/2002 | EP1198477A1 Prolactin-releasing peptide and method for regulating autonomic functions and treating pain |
| 04/24/2002 | EP1198468A1 Stabilized viral envelope proteins and uses thereof |
| 04/24/2002 | EP1198451A2 Substituted phenoxyacetic acids |
| 04/24/2002 | EP1198256A1 Peptide-lipid conjugates, liposomes and liposomal drug delivery |
| 04/24/2002 | EP1198255A1 Identification of compounds that modify transcriptional responses to hypoxia |
| 04/24/2002 | EP1198253A2 Biologically active materials |
| 04/24/2002 | EP1198251A1 Combination of an anti-ep-cam antibody with a chemotherapeutic agent |
| 04/24/2002 | EP1198235A1 Method of promoting bone growth with hyaluronic acid and growth factors |
| 04/24/2002 | EP1198233A1 Sulfonamide and sulfamide substituted imidazoquinolines |
| 04/24/2002 | EP1156787A4 Oxadiazole compounds and compositions for delivering active agents |
| 04/24/2002 | EP0851768B1 Interactive molecular conjugates |
| 04/24/2002 | EP0822813B1 A combination of a 5-ht uptake inhibitor with a selective 5-ht 1a antagonist |
| 04/24/2002 | CN1346368A Potassium channel interactors and uses therefor |
| 04/24/2002 | CN1346365A Macrocylic peptides active against the hepatitis C virus |
| 04/24/2002 | CN1346360A Phosphoramidate, and mono-di, and tri-phosphate esters of (1R, cis)-4-(6-amino-9H-purin-9-YL)-2-cyclopentene-1-methanol as antiviral agents |
| 04/24/2002 | CN1346352A 1-4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof |
| 04/24/2002 | CN1346348A Amide compounds and medicinal use thereof |
| 04/24/2002 | CN1346292A Treatment of thrombosis by combined useof a factor Xa inhibitor and aspirin, tissue plasminogen activator (TPA) a gpII/IIIA antagonist, low molecular weight heparin or heparin |
| 04/24/2002 | CN1346284A CD 40 binding molecules and CTL peptides for treating tumors |
| 04/24/2002 | CN1346282A Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as combination therapy method in treating neoplasia |
| 04/24/2002 | CN1346281A Method for a programmed controlled overain simulation protocol |
| 04/24/2002 | CN1346279A Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
| 04/24/2002 | CN1346278A Regulation of anaesthesia |
| 04/24/2002 | CN1346277A Use of a serenoa repens extract for the production of a medicament to treat prostate cancer |
| 04/24/2002 | CN1346276A Biodegradable and biocompatible polymeric microsphores encapsulating salmonella enteritidis bacteria |
| 04/24/2002 | CN1346275A Treatment of accidental extravasation of anthracyclines |
| 04/24/2002 | CN1346273A Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding |
| 04/24/2002 | CN1346270A Compositions having improved stability |
| 04/24/2002 | CN1346262A Antimicrobial wipes which provide improved immediate germ reduction |
| 04/24/2002 | CN1083453C Fused imidazole derivatives as emultidrug resistance modulators |
| 04/24/2002 | CN1083280C Novel targeted compositions for diagnostic and therapeutic use |
| 04/24/2002 | CN1083266C Total parenteral nutrition solution containing water-soluble vitamin B |
| 04/24/2002 | CN1083264C Pharmaceutical compositions comprising an opiate ant agonist and calcium salts, their use for the treatment of endorphin-mediated pathlogies |
| 04/23/2002 | US6376657 Pharmaceutical compositions having appetite suppressant activity |
| 04/23/2002 | US6376654 Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof |
| 04/23/2002 | US6376651 Amino acid sequences of a caf 1-related protein and to the use of these sequences in the diagnosis, treatment, and prevention of disorders associated with cell proliferation and inflammation. |
| 04/23/2002 | US6376550 Pharmaceutical compositions containing tramadol for migraine |
| 04/23/2002 | US6376549 Bioavailability; synergistic mixture |
| 04/23/2002 | US6376545 Tablet |
| 04/23/2002 | US6376536 Quaternary ammonium salts and their use |
| 04/23/2002 | US6376528 Synergistic mixture |
| 04/23/2002 | US6376517 For treating vision loss, preventing vision degeneration, and promoting vision regeneration (?neopsis?) |
| 04/23/2002 | US6376509 Melanocortin receptor agonists |
| 04/23/2002 | US6376508 Treatments for spinal muscular atrophy |
| 04/23/2002 | US6376502 Osteoporosis compounds |
| 04/23/2002 | US6376489 Cyclic AMP-specific phosphodiesterase inhibitors |
| 04/23/2002 | US6376482 Use of mesophase-stabilized compositions for delivery of cholesterol-reducing sterols and stanols in food products |
| 04/23/2002 | US6376478 N-acetylated (alpha)-linked acidic dipeptidase inhibitor; blocks release of glutamte pre-synaptically for reduced toxicity |
| 04/23/2002 | US6376476 Isoprenoid pathway inhibitors for stimulating bone growth |
| 04/23/2002 | US6376475 Inhibiting biosynthesis of sialyl galactosides involved in immune responses; for treating graft rejection, autoimmune diseases, and allergies |
| 04/23/2002 | US6376242 Reduce the number of circulating platelets to low or below normal levels. |
| 04/23/2002 | US6376224 Composition comprising inhibitor for membrane pumps and photoaffinity-labeled chemotherapeutic agent |
| 04/23/2002 | US6375994 Preparation of fiber, L-glutamine and a soy derivative for the purpose of enhancement of isoflavone bioavailability |
| 04/23/2002 | US6375989 Submucosa extracts |
| 04/23/2002 | US6375979 Treating parkinson's disease, attention deficit hyperactivity disorder, dementia, depression, schizophrenia and dysautonomia; monoamine oxidase b inhibitor |
| 04/23/2002 | US6375975 Pharmaceutical compositions for buccal and pulmonary application |
| 04/23/2002 | US6375946 Antitumor, viricides,nk cell activating cytokine or a nk cell activating flavonoid and a compound effective to inhibit the production or release of hydrogen peroxide selected from the group consisting of histamine, other h.sub.2 receptor |
| 04/23/2002 | CA2193149C Cationic therapuetic agents and delivery systems |
| 04/23/2002 | CA2042934C Treatment of ocular hypertension with an ocular synergistic combination |
| 04/20/2002 | CA2359383A1 Use of pdev inhibitors for improved fecundity in mammals |
| 04/18/2002 | WO2002031511A2 Modulation of ligand binding/enzymatic activity of alpha beta proteins |
| 04/18/2002 | WO2002031499A1 Detection of neurodegenerative disorders |
| 04/18/2002 | WO2002031201A2 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products |
| 04/18/2002 | WO2002031151A2 Lipocalins |
| 04/18/2002 | WO2002031146A2 Isolated human nuclear hormone receptors, nucleic acid molecules encoding human nuclear hormone receptors, and uses thereof |
| 04/18/2002 | WO2002031134A2 Novel serine protease genes related to dppiv |
| 04/18/2002 | WO2002031110A2 Hematopoietic stem cell gene therapy |
| 04/18/2002 | WO2002031109A2 Intracellular delivery of biological effectors by novel transporter peptide sequences |
| 04/18/2002 | WO2002031025A2 Biodegradable poly(beta-amino esters) and uses thereof |
| 04/18/2002 | WO2002030984A1 Human anti-epidermal growth factor receptor single-chain antibodies |
| 04/18/2002 | WO2002030981A1 Gene encoding a human g-protein coupled receptor and its use |
| 04/18/2002 | WO2002030906A1 Anti-tumour compounds |
| 04/18/2002 | WO2002030868A1 Selective maxi-k- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
| 04/18/2002 | WO2002030473A1 Targeted therapeutic agents |
| 04/18/2002 | WO2002030465A2 Compositions that inhibit proliferation of cancer cells |
| 04/18/2002 | WO2002030462A2 Hedgehog antagonists, methods and uses related thereto |
| 04/18/2002 | WO2002030461A2 Methods for treating disorders of the female reproductive system |
| 04/18/2002 | WO2002030455A2 Agents for the treatment of viral infections |